Figure 4.
Immuno-modulation strategies for ‘off-the-shelf’ clinical use of human pluripotent stem cell-derived beta cells. A universal product can be developed by combining gene editing for different strategies, such as HLA antigen disruption to reduce immunogenicity and insertion of double suicide switches to eliminate proliferative, non-committed progenitors as well as other pancreatic lineages, thereby enriching insulin-secreting beta cells.